The pharmaceutical industry has never had more data, but AI-powered drug development will not advance on data volume alone. Clinical trials, electronic health records, imaging archives, pathology reports, genomic repositories, …
Category:
Health
-
-
One takeaway from this year’s surge of biotech IPO activity is that investors want to see at least some clinical data before a company makes its stock market debut. Braveheart …
-
Welcome back to another episode of MedCity FemFwd, a podcast dedicated to exploring the breakthroughs and challenges in women’s health. In this episode, we’re joined by Cheryl Larson, president and …
-
Dear Medicaid Directors, State Leaders, and other invested collaborators who were awarded Rural Health Transformation (RHT) Grant funding, Your job is exhausting and tireless — you are seen and heard. …
-
While more than $2.5 billion has flowed into kidney-focused value-based care over the past 5-6 years hospital spending on kidney disease has not improved. The problem may not be the …
-
Healthcare has never been short on ideas. Today, headlines are dominated by AI tools entering clinical workflows and new care models reshaping how and where patients receive treatment. But speed …
-
As cold chain volumes surge, driven by the rise of GLP-1s, biologics and other temperature-sensitive therapies, pharmacies are under pressure to evolve. Central fill models offer clear advantages in speed, …
-
Although direct to consumer business models have had mixed success in healthcare historically, a report from Boston Consulting Group published earlier this year noted that some key guidelines have emerged …
-
A group of 47 senators — 45 Democrats and two independents — submitted a letter to the Centers for Medicare and Medicaid Services urging the Trump administration to withdraw the …
-
A closely watched Replimune cancer therapy now has FDA approval for treating advanced cases of melanoma, marking a comeback for the company and a drug whose future was uncertain after …